Atezolizumab Plus Bevacizumab in TMB-High Non−Small Cell Lung Cancers—The Hunt for Predictive Biomarkers to Optimize Treatment Selection
Mené sur 307 patients atteints d'un cancer du poumon non à petites cellules non épidermoïde de stade métastatique présentant une charge mutationnelle élévée, cet essai non randomisé de phase II évalue l'efficacité, du point de vue de la survie sans progression à 12 mois, et la toxicité d'un traitement de première ligne combinant atézolizumab et bévacizumab
Expression of programmed cell death 1 (PD-1) ligand 1 (PD-L1) on tumor cells represents the most widely used clinical biomarker for predicting response to immune checkpoint inhibition in non−small cell lung cancer (NSCLC). However, even among advanced NSCLCs with high PD-L1 expression on 50% or more of tumor cells, only a minority of patients will respond to treatment with first-line PD-L1 inhibitors, such as pembrolizumab, atezolizumab, and cemiplimab, highlighting the pressing need to identify more effective therapeutic strategies as well as more precise biomarkers of immunotherapy activity in lung cancer.
JAMA Oncology , commentaire, 2021